Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices

Ardura, Monica I.; Hartley, David; Dandoy, Christopher E.; Lehmann, Leslie; Jaglowski, Samantha; Auletta, Jeffery J.

doi:10.1016/j.bbmt.2020.04.018

Cited by 38 publications

(41 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several antiviral and immunomodulatory agents are currently under evaluation for the treatment of this infection [76,77]. In patients with oxygen saturation lower than 95%, dexamethasone for 10 days as well as remdesivir for 5 days is recommended in the last Infectious Disease Society of America (IDSA) guidelines [78].…”

Section: Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-cov-2)mentioning

confidence: 99%

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper

et al. 2020

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene ciloleucel and tisagenlecleucel) have been approved for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia; many other CART constructs are in research for both hematological and non-hematological diseases. Most of the patients receiving CART therapy will develop fever at some point after infusion, mainly due to cytokine release syndrome (CRS). The onset of CRS is often indistinguishable from an infection, which makes management of these patients challenging. In addition to the lymphodepleting chemotherapy and CAR T cells, the treatment of complications with corticosteroids and/or tocilizumab increases the risk of infection in these patients. Data regarding incidence, risk factors and prevention of infections in patients receiving CART cell therapy are scarce. To assist in patient care, a multidisciplinary team from hospitals designated by the Spanish Ministry of Health to perform CART therapy prepared these recommendations. We reviewed the literature on the incidence, risk factors, and management of infections in adult and pediatric patients receiving CART cell treatment. Recommendations cover different areas: monitoring and treatment of hypogammaglobulinemia, prevention, prophylaxis, and management of bacterial, viral, and fungal infections as well as vaccination prior and after CART cell therapy.

show abstract

Section: Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-cov-2)mentioning

confidence: 99%

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Current guidelines recommend delaying the planned allogenic stem cell transplant [32,33]. This is a unique situation where the donor and recipient both are at risk and a careful decision making keeping all factors into account be made.…”

Section: Stem Cell Transplantationmentioning

confidence: 99%

Caring for cancer patients in the Covid pandemic: choosing between the devil and deep sea

Chakraborty

Pandey

2020

World J Surg Onc

View full text Add to dashboard Cite

Background: Healthcare is an essential service at any time more so in the crisis like Covid. With increase in number of cases and mortality from Covid, the primary focus is shifted to the management of the Covid crisis and other health emergencies thus affecting normal health services and routine treatment of other diseases like cancer. Methods: This article reviews the published literature and guidelines on Covid and cancer and discusses them to optimize the care of cancer patients during Covid pandemic to improve treatment outcomes. Results: The results of the review of published literature show a twofold increase in probability of getting CoV2 infection by the cancer patients and a four-fold increase in chance of death. On the other hand, if left untreated a 20% increase in cancer death is expected. Data further show that none of the medicines like remdesivir, hydroxy chloroquin, dexamethasone, or azithromycin improves survival and response to Covid in cancer patients. Surgical results too show similar outcome before and after the pandemic though most of these report on highly selected patients populations. Conclusions: The Covid 2019 pandemic places cancer patients in a very difficult situation wherein if they seek treatment, they are exposing themselves to a risk of developing CoV2 infection and if they do not, the probability of dying without treatment increases. Hence, for them it is a choice between the devil and deep sea, and it is for the healthcare providers to triage patients and treat who cannot wait even though the data from the carefully selected cohort of patients show no increase in mortality or morbidity from treatment during Covid.

show abstract

“…Ces recommandations de bonnes pratiques émises par l'OMS, l'European Society for Blood and Marrow Transplant (EBMT) et l'American Society for Transplantation and Cellular Therapy (ASTCT) intéressent les patients devant bénéficier d'une greffe de CSH et leurs donneurs, mais également les patients en postgreffe de CSH et de thérapie CAR-T cells [14,15,17]. Ces lignes directrices visent à minimiser la propagation du virus (mesures « barrières », visites limitées, téléconsultations) [16], à protéger les donneurs et les receveurs de CSH, tout en offrant les soins nécessaires aux patients selon la balance bénéfice/ risque [18,19]. Celles-ci seront modifiées à mesure que de nouvelles informations deviendront disponibles, notamment davantage de données sur l'épidémiologie et les résultats cliniques, et l'efficacité des thérapies médicamenteuses [20,21].…”

Section: Recommandations Spécifiquesunclassified

COVID-19 et greffe de cellules souches hématopoïétiques : recommandations et situation au Maroc

2020

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices

Cited by 38 publications

References 118 publications

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper

Caring for cancer patients in the Covid pandemic: choosing between the devil and deep sea

COVID-19 et greffe de cellules souches hématopoïétiques : recommandations et situation au Maroc

Contact Info

Product

Resources

About